

## **COLON DISEASE ORIENTED GROUP**

CHELSEA HOTEL, TORONTO, ON ROOM: ROSSETTI ROOM

SATURDAY MAY 4<sup>TH</sup>, 2024 2:30 PM − 03:30 PM

CO-CHAIRS: DR JON LOREE & DR RACHEL GOODWIN SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

## CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

## Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To identify clinical trial research opportunities in malignancies of the colon within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to malignancies of the colon.
- To integrate and apply new clinical trial methodologies in malignancies of the colon in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators.

2:30 pm	Welcome	Dr Loree & Dr Goodwin	
2:35 pm	CRC.9 (NRG-GI005 / COBRA): Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer		Dr H Lim
2:40 pm	CRC.10 (CIRCULATE-US / NRG-GI 008): Colon Adjuvant Ch Based on Evaluation of Residual Disease	emotherapy	Dr J Loree
2:55 pm	CLEARANCE: ctDNA-Selected Adjuvant Therapy for Treate Cancer Metastases	ed Colorectal	Dr J Loree
3:05 pm	PREVAIL: Post-operative RAS Targeting Eli-002 7P Vaccina Resected Colorectal Cancer Liver Metastases	ation In	Dr J Loree
3:15 pm	ERASUR (Alliance 022101): Testing the Addition of Total A Therapy to Usual Systemic Therapy Treatment for Limited Colorectal Cancer		Dr R Goodwin
3:25 pm	NCTN Colon Task Force Update		Dr Loree & Dr Goodwin
3:30 pm	Meeting Adjourned		